Xero Limited (ASX: XRO) shares experienced a volatile trading day, briefly touching a new low before steadying, underscoring market anxieties surrounding the company’s growth strategy and profitability outlook. The stock’s recent performance reflects a complex interplay of factors, from acquisition costs to analyst downgrades.
Xero shares initially dipped to A$119.46, marking a new low, before recovering to close at A$122.22, a 0.11% decrease on the day. The stock has declined -20.71% over the past month, bringing its year-to-date losses to -27.49%. The A$120 level is now being closely watched as a potential support level.
Top Australian Brokers
- Pepperstone - Top Australian broker - Read our review
- eToro - Invest in ASX and international shares - Read our review
The recent downturn follows the release of Xero’s half-year results on November 13th, which, while showing a 20% increase in operating revenue to NZ$1.19 billion and a 12% rise in adjusted EBITDA to NZ$350.9 million, failed to reassure markets. The operating expense to revenue ratio was 72.8%, excluding the impact of the Melio acquisition, or 77% including transaction costs. Concerns have centered on North American performance and broader technology sector weakness.
A significant factor impacting market sentiment is Xero’s acquisition of U.S.-based payments provider Melio for US$2.5 billion, plus a potential US$0.5 billion earn-out. The deal was partially funded by a A$1.85 billion institutional placement and a A$129.5 million share purchase plan. While the acquisition is designed to bolster Xero’s U.S. presence, the substantial capital outlay has raised concerns.
Adding to the downward pressure, RBC Capital downgraded Xero from “Outperform” to “Sector Perform” in September, lowering the price target from A$230 to A$187. This downgrade reflected concerns about increasing business complexity and potential U.S. bank fees for data access. Reports of JPMorgan Chase considering fees on fintech companies for accessing its banking infrastructure have further amplified these worries.
Xero’s June 2024 offering of US$925 million in 1.625% senior unsecured convertible notes due 2031, with an initial conversion price of US$109.65 per share, also introduced potential dilution concerns for existing shareholders.
Despite the challenges, some analysts remain optimistic. Jefferies raised its price target to A$160.36, anticipating strong average revenue per user (ARPU) growth through price increases and enhanced product offerings. Citi also increased its price target by 9% to A$158.20, reiterating a “buy” rating based on the company’s lower annual cost base and better-than-expected financial results.
Xero faces a period of navigating integration challenges and market uncertainties, with its ability to deliver on projected growth and manage costs crucial to restoring market confidence.
